Equillium, Inc. (EQ) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

OncoCyte Corp.

Equillium, Inc.

Pieris Pharmaceuticals, Inc.

Coeptis Therapeutics Holdings, Inc.

Enlivex Therapeutics Ltd.

Cyclo Therapeutics, Inc.

Co-Diagnostics, Inc.

IN8bio, Inc.

Alaunos Therapeutics, Inc.

Unity Biotechnology, Inc.

Elevation Oncology, Inc.

Why is Equillium, Inc. ?

With a fall in Net Sales of -100%, the company declared Very Negative results in Jun 25

The company has declared negative results for the last 2 consecutive quarters
The company has declared negative results in Dec 24 after 2 consecutive negative quarters
NET SALES(9M) At USD 4.39 MM has Grown at -86.99%
OPERATING CASH FLOW(Y) Lowest at USD -22.14 MM
PRE-TAX PROFIT(Q) At USD -5.74 MM has Fallen at -1,326.28%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 26.27%, its profits have fallen by -15.3%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -1.74% over the previous quarter and currently hold 19.29% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Equillium, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Equillium, Inc.

20.9%

0.19

165.46%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

77.36%

EBIT Growth (5y)

4.87%

EBIT to Interest (avg)

-25.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.36

Sales to Capital Employed (avg)

1.89

Tax Ratio

2.65%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.04%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.28

EV to EBIT

0.05

EV to EBITDA

0.06

EV to Capital Employed

0.21

EV to Sales

-0.03

PEG Ratio

Dividend Yield

ROCE (Latest)

379.75%

ROE (Latest)

-132.23%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -222.23 %

-26What is not working for the Company

NET SALES(9M)

At USD 4.39 MM has Grown at -86.99%

OPERATING CASH FLOW(Y)

Lowest at USD -22.14 MM

PRE-TAX PROFIT(Q)

At USD -5.74 MM has Fallen at -1,326.28%

NET PROFIT(Q)

At USD -5.74 MM has Fallen at -1,326.28%

ROCE(HY)

Lowest at -146.92%

RAW MATERIAL COST(Y)

Grown by 101.01% (YoY

CASH AND EQV(HY)

Lowest at USD 26 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.71 times

Here's what is working for Equillium, Inc.

Debt-Equity Ratio

Lowest at -222.23 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Equillium, Inc.

Net Sales

At USD 4.39 MM has Grown at -86.99%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -5.74 MM has Fallen at -1,326.28%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -5.74 MM has Fallen at -1,326.28%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -22.14 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv

Lowest at USD 26 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 4.71 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 101.01% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales